Compounds (trivial name) | Benign tumor (a) (n = 9) | Malignant PTCs | P-value2 | ||||
---|---|---|---|---|---|---|---|
Stage I (b) (n = 11) | Stage III/IV (C) (n = 7) | P-value1 | a vs. b | a vs. c | b vs. c | ||
Estrone (E1) | 12.1 ± 11.3 | 2.9 ± 2.3 | 5.0 ± 6.5 | 0.053 | 0.020 | 0.091 | 0.791 |
17β-estradiol (E2) | 0.8 ± 0.6 | 0.4 ± 0.2 | 1.1 ± 1.3 | 0.416 | |||
Estriol (E3) | 1.7 ± 1.7 | 1.9 ± 1.7 | 6.2 ± 6.7 | 0.146 | |||
2-hydroxyestrone (2-OH-E1) | 2.2 ± 3.5 | 0.3 ± 0.3 | 0.7 ± 1.2 | 0.073 | |||
2-hydroxy-17β-estradiol (2-OH-E2) | 0.5 ± 0.4 | 0.1 ± 0.1 | 0.3 ± 0.2 | 0.052 | 0.031 | 0.536 | 0.085 |
4-hydroxyestrone (4-OH-E1) | 0.6 ± 0.5 | 0.3 ± 0.3 | 0.4 ± 0.4 | 0.558 | |||
4-hydroxy-17β-estradiol (4-OH-E2) | 0.5 ± 0.4 | 0.1 ± 0.1 | 0.2 ± 0.1 | 0.182 | |||
2-methoxyestrone (2-MeO-E1) | 1.6 ± 1.7 | 0.5 ± 0.4 | 0.6 ± 0.6 | 0.108 | |||
2-methoxy-17β-estradiol (2-MeO-E2) | 1.4 ± 1.1 | 0.4 ± 0.3 | 0.6 ± 0.4 | 0.034 | 0.012 | 0.114 | 0.285 |
4-methoxyestrone (4-MeO-E1) | 0.6 ± 0.8 | 0.1 ± 0.1 | 0.2 ± 0.4 | 0.011 | 0.004 | 0.174 | 0.179 |
4-methoxy-17β-estradiol (4-MeO-E2) | 0.3 ± 0.7 | 0.1 ± 0.1 | 0.2 ± 0.2 | 0.104 | |||
17-epiestriol (17-epi-E3) | 0.3 ± 0.3 | 0.1 ± 0.1 | 0.1 ± 0.1 | 0.029 | 0.016 | 0.142 | 0.425 |
16-epiestriol (16-epi-E3) | 0.7 ± 0.9 | 0.3 ± 0.2 | 0.9 ± 1.0 | 0.589 | |||
16α-hydroxyestrone (16α-OH-E1) | 0.9 ± 0.7 | 0.6 ± 0.6 | 0.8 ± 0.8 | 0.462 | |||
16-keto-17β-estradiol (16-keto-E2) | 0.7 ± 0.9 | 0.6 ± 0.6 | 0.7 ± 1.0 | 0.803 |